New research on mutation in yeast can enhance understanding of human diseases

June 19, 2008

DURHAM, N.H. - Yeast, a model organism heavily relied upon for studying basic biological processes as they relate to human health, mutates in a distinctly different pattern than other model organisms, a finding that brings researchers closer to understanding the role of evolutionary genetics in human diseases and cancer. The study, by researchers from the University of New Hampshire, Indiana University, Harvard University, and the University of Utah, appears in Proceedings of the National Academy of Science (PNAS) Online Early Edition this week (June 16 - 20, 2008).

"In biology, the mutation is an absolutely fundamental process, essential to evolution but also the source of all genetic disease," says Kelley Thomas, associate professor of biochemistry and director of the Hubbard Center for Genome Studies at the University of New Hampshire. "Despite its importance, we still don't know much about the basic processes of mutation." Cancers are caused by mutations, as are inherited diseases like Huntington's disease and fragile X syndrome, the most common inherited form of mental retardation.

"If we know more about the patterns of mutation, we'd be able to better understand the origins of these diseases - and maybe prevent them," says Thomas.

The researchers asked a fundamental question: "What is the baseline rate and spectrum of mutation in yeast?" They found that, like the previously studied mutations in the nematode Caenorhabditis elegans, the yeast Saccharomyces cerevisiae had a very high rate of mutation from generation to generation.

Its patterns of mutation, however, turned out to be unique. While C. elegans mutations were largely the result of inserting or deleting base pairs of DNA, yeast's patterns of mutation were characterized by changing one base pair for another. "That was really surprising, that we didn't find that adding or subtracting in yeast," says Thomas. He adds that the consequences of inserting and deleting base pairs can be much more dramatic than substituting one base pair for another.

Comparing the mutation rates and spectrums of these two model organisms informs researchers' assumptions about mutation relevant to human health. "We were surprised that there isn't a common spectrum of mutation," says Thomas. "However, it's exciting, because if we can describe patterns of mutation, maybe we can understand why some organisms, including people, are susceptible to certain mutations and not others."

The approach used in this study allows yeast to accumulate mutations in the near absence of natural selection. By doing this, cells with mutations that might otherwise be lost because their cell is outgrown by others can continue to survive and be analyzed for their mutations. With this study, Thomas and his colleagues overcome a major limitation to the study of mutation by using a new generation of sequencing technology that let them sequence the entire genome of each yeast strain and to identify the rare mutational events that have taken place. This way, the yeast accumulate mutations that might otherwise make them "bad yeast" - the weak survive - and look for them across the entire 10 million base pair genome.

"The beer you make with this yeast is horrible," Thomas jokes.
Indiana University's Michael Lynch was the principal investigator on this paper, "A Genome-wide view of the spectrum of spontaneous mutations in yeast." Thomas credits former UNH graduate student Shilpa Kulkarni and current graduate student Way Sung with contributing powerful bioinformatics work to this research, which he calls "a big computational problem" due to the volume of data. Other UNH contributors from the Hubbard Center were Krystalynne Morris and Kazufusa Okamoto. Daniel Hartl, Christian Landry and Erik Dopman from Harvard; Nicole Coffey from Indiana University; and W. Joseph Dickinson from the University of Utah also contributed. The work was supported by the National Institutes for Health.

The Hubbard Center for Genome Studies at the University of New Hampshire was established in 2001 to lead the development of genomics research at UNH. It is a leader in comparative and environmental genomics, with a special emphasis on novel model species.

University of New Hampshire

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to